Advertisement
Advertisement
XENE
Xenon Pharmaceuticals Inc
37.56
USDSponsored
-0.19
-0.50%
Nov 19, 15:59 UTC -5
Closed
After-Market
37.89
+0.33
+0.87%
Xenon Pharmaceuticals Inc (XENE) Earnings
XENE Earnings Reports
Positive Surprise Ratio
XENE beat 26 of 44 last estimates.
59%
Next Report
Date of Next Report
Feb 24, 2027
Estimate for Q4 26 (Revenue/ EPS)
$919.02K
/-$1.16
Implied change from Q3 26 (Revenue/ EPS)
--
/+4.50%
Implied change from Q4 25 (Revenue/ EPS)
--
/-11.45%
Xenon Pharmaceuticals Inc earnings per share and revenue
On Nov 09, 2026, XENE reported earnings of -1.11 USD per share (EPS) for Q3 26, beating the estimate of -1.15 USD, resulting in a 4.03% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +2.32% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 12 analysts forecast an EPS of -1.16 USD, with revenue projected to reach 919.02 thousand USD, implying an increase of 4.50% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Invivyd, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.13
Actual
-$0.10
Surprise
+26.47%

Neumora Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.20
Actual
-$0.18
Surprise
+10.54%

Instil Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.62
Surprise
-261.09%

AYTU BioPharma, Inc. Common Stock
Report Date
Nov 16, 2026 For Q1 27
Estimate
-$0.26
Actual
-$0.20
Surprise
+23.61%

Estrella Immunopharma, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.17
Surprise
-108.33%

Jasper Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.02
Actual
-$13.97
Surprise
-361.93%

Kyntra Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.61
Actual
-$3.42
Surprise
+5.49%

Lantern Pharma Inc. Common Stock
Report Date
Nov 17, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.81
Surprise
-126.89%

CNS Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.24
Surprise
+12.85%

Pulmatrix, Inc. Common Stock
Report Date
Nov 17, 2026 For Q3 26
Estimate
-Actual
-$0.34
Surprise
-
FAQ
What were Xenon Pharmaceuticals Inc's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Xenon Pharmaceuticals Inc reported EPS of -$1.11, beating estimates by 4.03%, and revenue of $0.00, 0% as expectations.
How did the market react to Xenon Pharmaceuticals Inc's Q3 2026 earnings?
The stock price moved up 2.32%, changed from $40.45 before the earnings release to $41.39 the day after.
When is Xenon Pharmaceuticals Inc expected to report next?
The next earning report is scheduled for Feb 24, 2027.
What are the forecasts for Xenon Pharmaceuticals Inc's next earnings report?
Based on 12
analysts, Xenon Pharmaceuticals Inc is expected to report EPS of -$1.16 and revenue of $919.02K for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.